Applicants

  • Carolyn Chapman

    Carolyn Riley Chapman, PhD MS, joined the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) in October 2023 (mrctcenter.org). She is a Member of the Faculty of the Department of Medicine at Harvard Medical School and Lead Investigator in the Division of Global Health Equity (DGHE), Department of Medicine, Brigham and Women’s Hospital. Her work involves collaboration with diverse stakeholders to identify and address challenges in the research and development of genetic technologies and precision medicine, including cell and gene therapies. Since April 2023, Dr. Chapman serves as Co-Chair of the ELSI-Dedicated Genome Engineering Workgroup at the Center for Synthetic Regulatory Genomics (SyRGe), led by Dr. Jef Boeke, the Sol and Judith Bergstein Director of the Institute of Systems Genetics and Professor, Department of Biochemistry and Molecular Pharmacology, at NYU Grossman School of Medicine. Prior to joining the MRCT Center, Carolyn worked at NYU Grossman School of Medicine in various roles. Immediately before joining the MRCT Center, she was Faculty in the Center for Human Genetics and Genomics at NYU Grossman School of Medicine with a primary appointment as Research Assistant Professor in the Department of Population Health (Division of Medical Ethics). In the past, Carolyn has worked as an Associate/Lecturer and as Interim Associate Director for the Columbia Bioethics program; as a business strategy management consultant in the biopharmaceuticals industry at L.E.K. Consulting; at a start-up biopharmaceutical company, Aton Pharma; and as a freelance science/medical writer. Carolyn graduated summa cum laude from Dartmouth College with a BA in Biology. She has a PhD in Genetics from Harvard University and an MS in Bioethics from Columbia University. She completed a postdoctoral fellowship in medical ethics at NYU Grossman School of Medicine and a Graduate Certificate in Survey Research at UConn’s School of Public Policy.

  • Javin Oza

    Engineering of cell-free systems, proteins & enzymes, and adopting bioengineering to the university classroom

  • Priyanka Nain

    I am Priyanka Nain, currently working as a postdoctoral researcher in the Chemical and Biomolecular Engineering Department at the University of Delaware. Here, my research revolves around finding innovative solutions that integrate synthetic biology, sustainability, and healthcare. My Ph.D. is from the Chemical Engineering Department at IIT Delhi, where I was developing strategies to improve the production of biotherapeutic proteins. I am deeply passionate about sustainable biomanufacturing. I thrive on the scientific challenges involved in scaling up bioprocesses, from optimizing cell lines and media to fine-tuning fermentation feeding and control strategies, and analytical methods. But I also care deeply about the broader impact – delivering products that are both effective and accessible and manufactured in the interest of the environment.

  • Sarah Hartley

    Technology governance is concerned with the decisions that shape how technology is funded, developed, regulated, tested, and deployed – it determines technology trajectories. My social science research takes a critical look at the politics and power in these governance decisions, particularly in efforts to open-up these expert spaces to diverse knowledge, values and visions through engagement and knowledge co-production – features that have become prevalent in technology governance in recent years. I’m particularly interested in the value tensions that exist in and between science and society when governance decisions are opened-up and, importantly, how to manage these tensions more effectively. I focus on the development and risk assessment of emerging technologies, particularly the biotechnologies (gene drive, genome-editing, genetic modification of animals, especially insects) and AL/digital technology applications in environment and agriculture. I am Co-Director of the Centre for Doctoral Training in Environmental Intelligence.

  • Willy A. Valdivia-Granda

    I am the founder of Orion Integrated Biosciences. I lead a group of researchers developing new techniques to decode microbes’ genomic information and map short DNA fragments to their source of origin, virulence, and possible genetic manipulation. My research includes the use of artificial intelligence algorithms including large language models, neural networks, and generative adversarial networks to design a new generation of biotentities for biotechnology applications. I also lead the advancement of a new generation of analytical tools for risk assessment and early warning of biothreats that can affect health, trade, and national security. This work includes processing large data sets from multiple sources, including geospatial, trade, news outlets, security, and economic signals and indicators using machine learning and artificial intelligence algorithms. I have research projects with collaborators in several countries within the European Union, New Zealand, Guinea, Ukraine, Colombia, and Brazil. I serve as a subject matter expert and adviser to several funding agencies and policymakers within the U.S. government, and Hong Kong Research Council overseeing funding programs of more than USD 200 Million. This role not only underscores the significance of our work but also facilitates the integration of computer science principles into the development of solutions for pressing global challenges in health and security.

  • Alexander Refsnes Andrassy

    Research in cell culture models and synthetic biology innovations

  • Tiara Rahayu

    Tiara is Biotechnology enthusiast. Loving the world with collaboration in science, content creator, leadership in community, moderator event, and science communicator. My interests are about Biomedical informatics, genetic for disease, cancer genomics and precision oncology such as biomarkers. I have a sharing platform on @ngolabs for expand my network and get out more knowledge. Now, I’m being student research in National Research and Innovation Agency for handling Biomarker of HPV.

  • Elizabeth Kellogg

    Elizabeth Kellogg did her undergraduate studies at UC Berkeley and received a PhD from the University of Washington, working on computational biology in the group of David Baker. She then became a postdoctoral fellow in the lab of Eva Nogales at UC Berkeley using cryo-electron microscopy. Her scientific background results in a scientific approach that seeks to understand biology with a quantitative perspective, relying on biological structure determination and design. Since starting her own group at Cornell University in 2019, Dr. Kellogg has sought to understand how transposons reshape genomes and how they can be repurposed as genome-editing tools. In particular, her group has investigated the behavior and molecular mechanisms of programmable, CRISPR-associated transposons (CASTs), to determine how DNA integration is regulated spatially and temporally in a genomic context, using a combination of biochemical, structural, single-molecule and genetic approaches. Among other honors, Dr. Kellogg was selected as Pew Biomedical Scholar in 2021 and received the 2023 Margaret Oakley Dayhoff Award from the Biophysical Society. She joined St. Jude as an Associate Member in 2023.

  • Geoff Baldwin

    Geoff Baldwin is Professor of Synthetic & Molecular Biology at Imperial College London, he is Co-Director of the Imperial College Centre for Synthetic Biology and Director of the EPSRC Centre for Doctoral Training in BioDesign Engineering. Research work in the Baldwin lab focuses on the development of synthetic biology approaches to facilitate the engineering of new biological systems for real-world applications. To this end he has developed foundational tools that transform our ability to rapidly prototype new biological designs, like DNA-BOT, automated DNA assembly based on the BASIC method. These fundamental developments are being applied across a broad range of projects that address gene circuit design; RNA feedback control and in vivo directed evolution for the generation of new protein specificity and functionality. Recently he has been developing new AI based approaches to enhance our ability to engineer new biological systems with human interpretable outcomes and only sparse sampling of the design space.

  • Robert Ziman

    Robert is a research software engineer with a decade of experience supporting bioinformatics and computational biology projects in both academia and industry. He was a bioinformatics programmer at The Centre for Applied Genomics in Toronto, a bioinformatics associate at Genentech in South San Francisco, and a research associate in the Cohen Lab for Aging, Systems, and Statistics at the University of Sherbrooke in Quebec. He co-founded and co-hosted the Longevity Biotech Show podcast and has been observing the longevity biotech scene since the early 2000s. Robert holds a B.A.Sc. in Engineering Science from the University of Toronto.

  • Dr. Muhammad Saad Ahmed

    The main research interest of Dr. Ahmed is to focus on industrially important metabolites production in microbes through the application of system metabolic engineering and synthetic biology. Previously, Dr. Ahmed developed industrially competitive microbial strains that were capable of producing industrially important secondary metabolites, for instance, β-amyrin, squalene, etc., and these strains are highly efficient for commercialization. Moreover, Dr. Ahmed expanded his research interest toward other industrially important metabolites, i.e., fragrance, flavor, and drugs, that might be in the category of alkaloids, sesquiterpenoids, monoterpenoids, diterpenoids, triterpenoids, and tetraterpenoids. These metabolites are normally used in pharmaceuticals, nutraceuticals, and cosmeceuticals industries as raw materials for the production of medicines, foods, and cosmetics.

  • Bojing Jiang

  • Jason Kang

  • Ryuichi Hirota

    I am interested in the biosafety measure for the safer use of genetically modified bacteria. By controlling bacterial growth and survival using the engineered metabolic pathway for phosphorus, we developed novel biocontainment strategy which is robust, economical, and easy to apply.

  • Abhilash Patel

  • Luis Figueroa

    Degree in Biology from the Universidad Veracruzana, Mexico. Master’s degree in Bioethics from the Anahuac University, Mexico. Doctorate in Sciences from the Scientific Research Center of Yucatán A.C., Mérida, Yucatán. Mexico. Postdoctoral fellow at the Donald Danforth Plant Science Center. St.Louis Missouri, United States.
    Currently:
    -Titular Type A Researcher at the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ), Zapopan Headquarters. Department of Industrial Biotechnology, Zapopan, Jalisco, Mexico. Distinction by the National System of Researchers (SNI I).
    -General Coordinator of the “National Network of Synthetic Biology of Mexico”.
    -Coordinator of the research sub-line “Synthetic Biology” within the Department of Industrial Biotechnology of the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ). In the working group, state-of-the-art sequencing (Oxford Nanopore Technologies) is performed in yeast and bioinformatic analysis of omics data (genome, transcriptome, metagenome). Design of transformation systems through synthesis and Gibson assembly. We use CRISPR-Cas9, dCas9 and Cas13, in order to edit or regulate genes to check functionality in cell lines of animals, bacteria, yeast, marine organisms and plants.

  • Luis Figueroa-Yáñez

    Degree in Biology from the Universidad Veracruzana, Mexico. Master’s degree in Bioethics from the Anahuac University, Mexico. Doctorate in Sciences from the Scientific Research Center of Yucatán A.C., Mérida, Yucatán. Mexico. Postdoctoral fellow at the Donald Danforth Plant Science Center. St.Louis Missouri, United States.
    Currently:
    -Titular Type A Researcher at the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ), Zapopan Headquarters. Department of Industrial Biotechnology, Zapopan, Jalisco, Mexico. Distinction by the National System of Researchers (SNI I).
    -General Coordinator of the “National Network of Synthetic Biology of Mexico”.
    -Coordinator of the research sub-line “Synthetic Biology” within the Department of Industrial Biotechnology of the Center for Research and Assistance in Technology and Design of the State of Jalisco A.C. (CIATEJ). In the working group, state-of-the-art sequencing (Oxford Nanopore Technologies) is performed in yeast and bioinformatic analysis of omics data (genome, transcriptome, metagenome). Design of transformation systems through synthesis and Gibson assembly. We use CRISPR-Cas9, dCas9 and Cas13, in order to edit or regulate genes to check functionality in cell lines of animals, bacteria, yeast, marine organisms and plants.

  • Dr. DEBASHIS DUTTA

    Having earned my B.Tech in Food Technology from Jadavpur University, Kolkata, I got the opportunity to join the School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University) Varanasi, as M.Tech graduate and later got Ph.D under the supervision of Prof. Mira Debnath Das. I earned Ph.D (Biochemical Engineering) on an exceptionally well researched project on “Bioprocess strategy development on production and characterization of antifungal protein from Aspergillus giganteus”.

  • Tayyaba Zainab

    I have completed my PhD in Molecular Genetics from King’s College London, UK, I came back to Pakistan to join University Institute of Biochemistry and Biotechnology, PMAS-Arid Agriculture University Rawalpindi, Pakistan. I established my research group in 2016 and became the first person in our Institution to work on CRISPR based genome editing. Currently leading my team in establishing the National Center of Industrial Biotechnology at our Institution to further strengthen my work in Metabolic Engineering/Synthetic Biology.

    • Back to top ⇑